Business Matters: Eclipsed by Catastrophe

by G. Steven Burrill at Burrill & Company Despite stimulating and positive news for biotech product approvals and high-value deals this quarter, market performance has been shaped by the terrorist attacks and their aftermath.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

almost 24 years ago

Article

Systematic Troubleshooting for LC/MS/MS: Part 1, Sample Preparation and Chromatography

almost 24 years ago

Article

Designs for Bioassays with Plate Location Effects

almost 24 years ago

Article

Liposomes (a Review), Part One: Manufacturing Issues

almost 24 years ago

Article

Simplifying Pharmacologic Analysis with Programmable Scientific Software

almost 24 years ago

Article

Outsourcing Outlook: Truth in Outsourcing

almost 24 years ago

Article

Employing Murine MAbs as Ancillary Products in Cell Therapy Manufacturing, Part 2, A Case Study

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Business Matters: Eclipsed by Catastrophe

Articles in this issue

Newsletter

Trending on BioPharm International

Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress

Analytics, Automation, and Quality Driving the Next Era of Drug Development

Therapeutic Nucleic Acids: Advanced Solutions for Downstream Processing & Analysis